Log In
Print
BCIQ
Print
Print this Print this
 

ICT-121

  Manage Alerts
Collapse Summary General Information
Company ImmunoCellular Therapeutics Ltd.
DescriptionCancer stem cell vaccine that stimulates a cytotoxic T lymphocyte (CTL) response to CD133
Molecular Target Prominin 1 (PROM1) (CD133)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationBrain cancer
Indication DetailsTreat recurrent glioblastoma; Treat recurrent glioblastoma multiforme (GBM)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today